Sarepta Therapeutics Inc (SRPT) - Total Liabilities
Based on the latest financial reports, Sarepta Therapeutics Inc (SRPT) has total liabilities worth $1.67 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sarepta Therapeutics Inc - Total Liabilities Trend (1995–2025)
This chart illustrates how Sarepta Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Sarepta Therapeutics Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Sarepta Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Sarepta Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LandBridge Company LLC
NYSE:LB
|
USA | $554.12 Million |
|
Wuxi Rural Commercial Bank Co Ltd
SHG:600908
|
China | CN¥267.88 Billion |
|
Addus HomeCare Corporation
NASDAQ:ADUS
|
USA | $319.54 Million |
|
Melco Resorts & Entertainment Limited
F:MAS
|
Germany | €8.29 Billion |
|
Wuxi Paike New Materials Technology Co Ltd
SHG:605123
|
China | CN¥3.58 Billion |
|
BCO LATINOAMER.D.COM.EX.E
F:D8Q
|
Germany | €12.03 Billion |
|
Petrovietnam Power Corp
VN:POW
|
Vietnam | ₫51.37 Trillion |
|
Fibra Terrafina
MX:TERRA13
|
Mexico | MX$19.87 Billion |
Liability Composition Analysis (1995–2025)
This chart breaks down Sarepta Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Sarepta Therapeutics Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sarepta Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sarepta Therapeutics Inc (1995–2025)
The table below shows the annual total liabilities of Sarepta Therapeutics Inc from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.21 Billion | -9.29% |
| 2024-12-31 | $2.44 Billion | +1.26% |
| 2023-12-31 | $2.41 Billion | -12.33% |
| 2022-12-31 | $2.74 Billion | +23.58% |
| 2021-12-31 | $2.22 Billion | -0.13% |
| 2020-12-31 | $2.22 Billion | +121.27% |
| 2019-12-31 | $1.00 Billion | +64.75% |
| 2018-12-31 | $609.80 Million | +17.55% |
| 2017-12-31 | $518.75 Million | +493.44% |
| 2016-12-31 | $87.41 Million | +4.77% |
| 2015-12-31 | $83.44 Million | +76.10% |
| 2014-12-31 | $47.38 Million | +6.77% |
| 2013-12-31 | $44.38 Million | -45.43% |
| 2012-12-31 | $81.31 Million | +248.22% |
| 2011-12-31 | $23.35 Million | -52.14% |
| 2010-12-31 | $48.79 Million | +34.06% |
| 2009-12-31 | $36.40 Million | +271.25% |
| 2008-12-31 | $9.80 Million | -20.01% |
| 2007-12-31 | $12.26 Million | +288.98% |
| 2006-12-31 | $3.15 Million | +14.66% |
| 2005-12-31 | $2.75 Million | +22.15% |
| 2004-12-31 | $2.25 Million | -40.03% |
| 2003-12-31 | $3.75 Million | -26.77% |
| 2002-12-31 | $5.12 Million | +56.11% |
| 2001-12-31 | $3.28 Million | +90.45% |
| 2000-12-31 | $1.72 Million | +72.28% |
| 1999-12-31 | $1.00 Million | -16.67% |
| 1998-12-31 | $1.20 Million | +140.00% |
| 1997-12-31 | $500.00K | -85.29% |
| 1996-12-31 | $3.40 Million | +1033.33% |
| 1995-12-31 | $300.00K | -- |
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 ski… Read more